Therapeutic hypothermia after out-of-hospital cardiac arrest in children by Moler, F. W. et al.
Journal Articles Donald and Barbara Zucker School of MedicineAcademic Works
2015
Therapeutic hypothermia after out-of-hospital
cardiac arrest in children
F. W. Moler
F. S. Silverstein
R. Holubkov
B. S. Slomine
J. R. Christensen
See next page for additional authors
Follow this and additional works at: https://academicworks.medicine.hofstra.edu/articles
Part of the Pediatrics Commons
This Article is brought to you for free and open access by Donald and Barbara Zucker School of Medicine Academic Works. It has been accepted for
inclusion in Journal Articles by an authorized administrator of Donald and Barbara Zucker School of Medicine Academic Works. For more
information, please contact academicworks@hofstra.edu.
Recommended Citation
Moler F, Silverstein F, Holubkov R, Slomine B, Christensen J, Nadkarni V, Meert K, Schleien C, Dean J, . Therapeutic hypothermia
after out-of-hospital cardiac arrest in children. . 2015 Jan 01; 372(20):Article 2832 [ p.]. Available from:
https://academicworks.medicine.hofstra.edu/articles/2832. Free full text article.
Authors
F. W. Moler, F. S. Silverstein, R. Holubkov, B. S. Slomine, J. R. Christensen, V. M. Nadkarni, K. L. Meert, C. L.
Schleien, J. M. Dean, and +35 additional authors
This article is available at Donald and Barbara Zucker School of Medicine Academic Works:
https://academicworks.medicine.hofstra.edu/articles/2832
Therapeutic Hypothermia after Out-of-Hospital Cardiac Arrest in 
Children
Frank W. Moler, M.D., Faye S. Silverstein, M.D., Richard Holubkov, Ph.D., Beth S. Slomine, 
Ph.D., James R. Christensen, M.D., Vinay M. Nadkarni, M.D., Kathleen L. Meert, M.D., Amy 
E. Clark, M.S., Brittan Browning, M.S., R.D., C.C.R.C., Victoria L. Pemberton, R.N.C., M.S., 
Kent Page, M.Stat., Seetha Shankaran, M.D., Jamie S. Hutchison, M.D., Christopher J.L. 
Newth, M.D., Kimberly S. Bennett, M.D., M.P.H., John T. Berger, M.D., Alexis Topjian, M.D., 
Jose A. Pineda, M.D., Joshua D. Koch, M.D., Charles L. Schleien, M.D., M.B.A., Heidi J. 
Dalton, M.D., George Ofori-Amanfo, M.B., Ch.B., Denise M. Goodman, M.D., Ericka L. Fink, 
M.D., Patrick McQuillen, M.D., Jerry J. Zimmerman, M.D., Ph.D., Neal J. Thomas, M.D., Elise 
W. van der Jagt, M.D., M.P.H., Melissa B. Porter, M.D., Michael T. Meyer, M.D., Rick 
Harrison, M.D., Nga Pham, M.D., Adam J. Schwarz, M.D., Jeffrey E. Nowak, M.D., Jeffrey 
Alten, M.D., Derek S. Wheeler, M.D., Utpal S. Bhalala, M.D., Karen Lidsky, M.D., Eric Lloyd, 
M.D., Mudit Mathur, M.D., Samir Shah, M.D., Theodore Wu, M.D., Andreas A. Theodorou, 
M.D., Ronald C. Sanders Jr., M.D., and J. Michael Dean, M.D., M.B.A. for the THAPCA Trial 
Investigators*
Abstract
Background—Therapeutic hypothermia is recommended for comatose adults after witnessed 
out-of-hospital cardiac arrest, but data about this intervention in children are limited.
Methods—We conducted this trial of two targeted temperature interventions at 38 children’s 
hospitals involving children who remained unconscious after out-of-hospital cardiac arrest. Within 
6 hours after the return of circulation, comatose patients who were older than 2 days and younger 
than 18 years of age were randomly assigned to therapeutic hypothermia (target temperature, 
33.0°C) or therapeutic normothermia (target temperature, 36.8°C). The primary efficacy outcome, 
survival at 12 months after cardiac arrest with a Vineland Adaptive Behavior Scales, second 
edition (VABS-II), score of 70 or higher (on a scale from 20 to 160, with higher scores indicating 
better function), was evaluated among patients with a VABS-II score of at least 70 before cardiac 
arrest.
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Results—A total of 295 patients underwent randomization. Among the 260 patients with data 
that could be evaluated and who had a VABS-II score of at least 70 before cardiac arrest, there 
was no significant difference in the primary outcome between the hypothermia group and the 
normothermia group (20% vs. 12%; relative likelihood, 1.54; 95% confidence interval [CI], 0.86 
to 2.76; P = 0.14). Among all the patients with data that could be evaluated, the change in the 
VABS-II score from baseline to 12 months was not significantly different (P = 0.13) and 1-year 
survival was similar (38% in the hypothermia group vs. 29% in the normothermia group; relative 
likelihood, 1.29; 95% CI, 0.93 to 1.79; P = 0.13). The groups had similar incidences of infection 
and serious arrhythmias, as well as similar use of blood products and 28-day mortality.
Conclusions—In comatose children who survived out-of-hospital cardiac arrest, therapeutic 
hypothermia, as compared with therapeutic normothermia, did not confer a significant benefit in 
survival with a good functional outcome at 1 year. (Funded by the National Heart, Lung, and 
Blood Institute and others; THAPCA-OH ClinicalTrials.gov number, NCT00878644.)
Out-of-hospital cardiac arrest in children often results in death or in poor long-term 
functional outcome in survivors.1–3 In 2002, two trials involving adults showed that 
therapeutic hypothermia improved neurologic outcomes in comatose survivors after out-of-
hospital cardiac arrest with ventricular fibrillation or ventricular tachycardia.4,5 International 
guidelines recommend therapeutic hypothermia for adults with out-of-hospital cardiac arrest 
who have similar characteristics.6,7 Recently, another trial involving adults after out-of-
hospital cardiac arrest showed that therapeutic hypothermia with the use of a target 
temperature of 33°C, as compared with actively maintained therapeutic normothermia 
(36°C), did not improve outcomes.8 The fundamental difference between this recent trial 
and the earlier 2002 trials was the active intervention to prevent fever in the comparison 
group of patients who were treated with normothermia.4,5,8
Published results of randomized trials of therapeutic hypothermia in children after out-of-
hospital cardiac arrest are lacking.9 In observational studies, therapeutic hypothermia has not 
been associated with improved outcomes in children after cardiac arrest.10–12 Moreover, one 
trial involving pediatric patients with traumatic brain injury showed a trend toward increased 
mortality in the hypothermia group.13 There are significant differences between adult and 
pediatric populations with out-of-hospital cardiac arrest, and results cannot be generalized 
between age groups.14 We report results of the Therapeutic Hypothermia after Pediatric 
Cardiac Arrest Out-of-Hospital (THAPCA-OH) trial, which compared the efficacy of 
therapeutic hypothermia (target temperature, 33.0°C) with that of therapeutic normothermia 
(target temperature, 36.8°C).15,16
METHODS
STUDY DESIGN AND OVERSIGHT
This randomized clinical trial, which was conducted in pediatric intensive care units (ICUs) 
at 38 children’s hospitals in the United States and Canada, involved children who were 
admitted after out-of-hospital cardiac arrest. The rationale, study design, outcome selection 
process, protocol summary, and 12-month pilot vanguard phase have been described 
previously.15–17
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The trial was funded by the National Heart, Lung, and Blood Institute (NHLBI). The 
protocol was designed by the first, third, and last authors. The institutional review board at 
each participating site and the data coordinating center at the University of Utah (see the 
Supplementary Appendix, available with the full text of this article at NEJM.org) approved 
the protocol and informed-consent documents.
The site research coordinators listed in the Supplementary Appendix collected all the data, 
and statisticians at the data coordinating center performed all the analyses. Details of site 
training, data management, and site monitoring are provided in the Supplementary 
Appendix. An independent data and safety monitoring board that was appointed by the 
NHLBI conducted interim safety and efficacy analyses.18 All the authors vouch for the 
accuracy and completeness of the submitted data, the third and last authors vouch for the 
data management and statistical analyses, and all the authors vouch for the fidelity of this 
report to the study protocol, which is available at NEJM.org.
PATIENT POPULATION
Children older than 48 hours and younger than 18 years of age were eligible for inclusion in 
the study if they had a cardiac arrest requiring chest compressions for at least 2 minutes and 
remained dependent on mechanical ventilation after the return of circulation. Major 
exclusion criteria were the inability to undergo randomization for any reason within 6 hours 
after the return of circulation, a score of 5 or 6 on the Glasgow Coma Scale motor-response 
subscale (on which scores range from 1 to 6, with lower scores indicating reduced levels of 
function), the decision by the clinical team to withhold aggressive treatment, and major 
trauma associated with the cardiac arrest. A full listing of the exclusion criteria is provided 
in the Supplementary Appendix. Written informed consent from a parent or legal guardian 
was obtained for each participant.
RANDOMIZATION AND INTERVENTION
Eligible patients were randomly assigned in a 1:1 ratio to either therapeutic hypothermia or 
therapeutic normothermia. Randomization was performed with the use of permuted blocks 
stratified according to clinical center and age at entry (<2 years, 2 to <12 years, and ≥12 
years).
Targeted temperature management was actively maintained for 120 hours in each group. 
Children who were assigned to therapeutic hypothermia were pharmacologically paralyzed 
and sedated, and a Blanketrol III temperature management unit (Cincinnati Sub-Zero) was 
used, with blankets applied anteriorly and posteriorly, to achieve and maintain a core 
temperature of 33.0°C (range, 32.0 to 34.0) for 48 hours. The children were then rewarmed 
over a period of 16 hours or longer to a target temperature of 36.8°C (range, 36.0 to 37.5); 
this temperature was actively maintained throughout the remainder of the 120-hour 
intervention period. Children who were randomly assigned to therapeutic normothermia 
received identical care except that the core temperature was actively maintained with the 
cooling unit at 36.8°C (range, 36.0 to 37.5) for 120 hours.
Dual monitoring of the central temperature (esophageal, rectal, or bladder temperature) and 
an automatic mode on the temperature management unit were used for all the patients. The 
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probe connected to the cooling unit was designated to be the primary probe; the other probe 
was connected to the bedside monitor for safety backup. In three patients who received 
extracorporeal membrane oxygenation (ECMO) at the time of randomization, ECMO was 
used for temperature control. All other aspects of clinical care were determined by the 
clinical teams.
OUTCOMES
The primary outcome was survival with a good neurobehavioral outcome at 12 months of 
follow-up. A good neurobehavioral outcome was defined as an age-corrected standard score 
of 70 or higher on a scale of 20 to 160 on the Vineland Adaptive Behavior Scales, second 
edition (VABS-II).19 The VABS-II has an age-corrected mean score of 100 and a standard 
deviation of 15; higher scores indicate better function. The VABS-II data were collected 
centrally at the Kennedy Krieger Institute by means of telephone interviews conducted by a 
trained interviewer who was unaware of the treatment assignments.
As prespecified in the trial protocol, enrolled children whose reported VABS-II scores were 
less than 70 before cardiac arrest (on the basis of data from a standardized caregiver 
questionnaire completed by a parent or guardian at each site within 24 hours after 
randomization) were not included in the primary efficacy analysis. Patients for whom no 
baseline VABS-II score was available were considered to be eligible for the primary 
analysis if the baseline Pediatric Overall Performance Category (POPC) and Pediatric 
Cerebral Performance Category (PCPC) scores20 were in the normal or mild disability 
category.17,21 Both scales range from 1 to 6, with lower scores indicating less disability; 
patients with scores of either 1 or 2 on both scales were eligible for the primary analysis.
Secondary outcomes were survival 12 months after cardiac arrest and change in 
neurobehavioral function, measured as the difference between the baseline level before 
cardiac arrest and the 12-month measurement on the VABS-II. For the latter, patients who 
had died and patients with the lowest possible VABS-II score were assigned the worst 
possible outcomes, regardless of baseline function.
A global cognitive score that was based on results of on-site neuropsychological testing was 
a tertiary outcome (see the Supplementary Appendix). Safety outcomes included the 
incidences of blood-product use, infection, and serious arrhythmias through 7 days and 28-
day mortality. Details of the methods used for the assessment of outcomes are provided in 
the Supplementary Appendix.
STATISTICAL ANALYSIS
The target sample size was calculated on the basis of an absolute effect size of 15 to 20%, 
with an estimated primary outcome rate of 15 to 35% in the normothermia group. Assuming 
that 5% of the patients would be excluded owing to a baseline neurologic deficit and that 5% 
of patients would be lost to follow-up, we estimated that 276 patients would need to be 
enrolled to provide the study with 85% power to detect a 20% treatment effect.
The efficacy analysis for the primary outcome was performed with the use of a prespecified 
modified intention-to-treat approach, excluding children with poor neurobehavioral function 
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before cardiac arrest, as noted above. Secondary efficacy outcomes were analyzed in all the 
children. Safety analyses were performed according to the treatment received in treated 
patients only. The primary outcome and 12-month mortality were compared between the 
treatment groups with the use of a Cochran–Mantel–Haenszel test stratified according to age 
category.
The change in the VABS-II score was analyzed with the use of van Elteren’s modification of 
the Mann–Whitney test,22 with stratification according to age category, treatment of death as 
the worst outcome, and treatment of the lowest possible VABS-II score at 1 year as the 
second worst outcome. An alpha level of 0.05 was set for the primary analysis, and an alpha 
level of 0.025 was set for each of the two formal secondary analyses, with two-sided tests 
used in all instances. The probability of survival to 1 year was evaluated by comparing 
survival curves over time between treatment groups with the use of a log-rank test stratified 
according to age category. All analyses were performed with the use of SAS software, 
version 9.3 (SAS Institute).
RESULTS
PATIENTS
Between September 1, 2009, and December 31, 2012, we identified 1355 patients who were 
screened for eligibility and met the trial inclusion criteria (Fig. 1). Of these patients, 475 
were eligible to enroll in the study. The families of 411 of these patients were approached 
for consent, 299 families consented, and 295 patients underwent randomization at 36 sites in 
the United States and Canada (2 sites did not enroll any patients). Of the patients who 
underwent randomization to targeted temperature management, 155 were assigned to 
therapeutic hypothermia and 140 were assigned to therapeutic normothermia. A total of 3 
patients who were assigned to therapeutic hypothermia did not receive an intervention, and 1 
patient assigned to therapeutic normothermia received hypothermia therapy.
Of the 295 patients who underwent randomization, 13 in the hypothermia group and 12 in 
the normothermia group were ineligible for the primary outcome analysis owing to baseline 
VABS-II scores that were less than 70, or POPC or PCPC scores that were 3 or higher. At 
12 months, vital status was not known in 4 patients in each group, and 2 additional surviving 
children in the normothermia group did not undergo VABS-II testing (Fig. 1). Therefore, 
260 patients had data that could be evaluated for the primary outcome.
CHARACTERISTICS AT BASELINE AND TEMPERATURE INTERVENTION
The characteristics of the patients in the hypothermia group and those in the normothermia 
group were similar at baseline (Table 1, and Table S1 in the Supplementary Appendix). The 
median age of the patients was 2 years; two thirds of the patients were male. Bystanders 
witnessed the cardiac arrest in 39% of the patients and performed cardiopulmonary 
resuscitation in 66% of them. The initial rhythm was ventricular fibrillation or ventricular 
tachycardia in 8% of the patients. Baseline functional status based on the VABS-II, PCPC, 
and POPC scores is shown in Table S2 in the Supplementary Appendix.
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The median time from the return of circulation to the initiation of treatment was 5.9 hours 
(interquartile range, 5.2 to 6.7) in the hypothermia group and 5.8 hours (interquartile range, 
5.0 to 6.4) in the normothermia group. Figure 2 shows the primary central (core) 
temperatures recorded for the two groups. Additional information regarding temperature 
control is provided in the Supplementary Appendix.
OUTCOMES
The proportion of survivors with VABS-II scores of 70 or more at 12 months was not 
significantly different between the two groups (20% in the hypothermia group vs. 12% in 
the normothermia group; relative likelihood, 1.54; 95% confidence interval [CI], 0.86 to 
2.76; P = 0.14) (Table 2). Sensitivity analyses, including a per-protocol analysis and 
analyses with imputation of missing data, did not alter the primary-outcome result (see the 
Supplementary Appendix).
The secondary outcome of change in the VABS-II score from baseline to 12 months also did 
not differ significantly between the two groups (P = 0.13). The overall proportion of patients 
with 12-month VABS-II scores that did not decrease by more than 15 points (1 SD) of their 
baseline measurements was similar in the hypothermia group and the normothermia group 
(14% and 13%) (Table 2).
Mortality among all patients who underwent randomization and whose vital status was 
known (287 of 295 patients [97%]) was assessed at 12 months. Survival at 1 year did not 
differ significantly between the groups (38% in the hypothermia group vs. 29% in the 
normothermia group; relative likelihood, 1.29; 95% CI, 0.93 to 1.79; P = 0.13) (Table 2). 
Survival over time was significantly longer with therapeutic hypothermia than with 
therapeutic normothermia (mean survival, 149±14 days vs. 119±14 days; P = 0.04 for the 
comparison of survival between the two treatment groups by means of the log-rank test) 
(Fig. S1 in the Supplementary Appendix). The primary cause of death was brain death or 
withdrawal of life-sustaining therapy owing to a poor neurologic prognosis in the majority 
of patients in the two groups (82% of the patients in the hypothermia group and 79% of the 
patients in the normothermia group) (Table S3 in the Supplementary Appendix).
Data on global cognitive functioning in survivors are shown in Table S4 in the 
Supplementary Appendix. Results of the Early Learning Composite score from the Mullen 
Scales of Early Learning23 did not differ significantly between the survivors in the 
hypothermia group and those in the normothermia group; there were also no significant 
between-group differences in the IQ score24 distributions on the Wechsler Abbreviated 
Scale of Intelligence or in the combined categories from both the Mullen and the Wechsler 
tests.
SAFETY
The incidences of infection, bleeding, and serious arrhythmias within 7 days after 
randomization were similar in the 153 patients who received hypothermia therapy and the 
139 who received normothermia therapy (Table 3). Mortality at 28 days was also not 
significantly different in the two groups (57% in the hypothermia group vs. 67% in the 
normothermia group, P = 0.08). Additional data regarding adverse events are provided in 
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Table S5 in the Supplementary Appendix. Hypokalemia and thrombocytopenia occurred 
more frequently in the hypothermia group, and renal-replacement therapy was used more 
often in the normothermia group.
DISCUSSION
The THAPCA-OH trial evaluated the efficacy of therapeutic hypothermia (targeted 
temperature management at 33.0°C) and therapeutic normothermia (targeted temperature 
management at 36.8°C) to improve outcomes after out-of-hospital cardiac arrest in children. 
There was no significant between-group difference in the primary outcome of survival with 
a good neurobehavioral outcome (VABS-II composite score of ≥70) at 12 months. The 
secondary outcome, the change in the VABS-II score from baseline to 1 year, did not differ 
between the groups; the proportion of children with VABS-II scores that decreased no more 
than 15 points (1 SD) from their baseline scores was similar in the two groups. All-cause 
mortality at 1 year also did not differ significantly between the two groups, although 
survival analysis through 365 days showed a significant difference in survival time in favor 
of therapeutic hypothermia.
One important potential limitation of the trial is that, on the basis of the observed confidence 
limits for treatment differences, a potentially important clinical benefit cannot be ruled out 
despite the lack of a significant difference in the primary outcome measure. A larger trial 
might have detected or rejected a smaller intervention effect. Indeed, there was a significant 
difference in survival time with therapeutic hypothermia, although this was a secondary 
outcome measure.
Other trial limitations should also be noted. Caregivers and research staff in the ICU could 
not be unaware of the treatment assignments of the patients, although the primary outcome 
assessments were blinded. We could not rule out the possibility of earlier death or 
determination by clinical teams of futility in the normothermia group. Patients in the 
hypothermia group may have survived longer because prognostic assessments were delayed 
until normothermia was achieved. For logistical reasons, we did not conduct a preclinical 
trial site phase-in or use only high-enrolling sites; such strategies have been suggested in 
other hypothermia trials.13,25–28
Our overall findings are consistent with those of a previous clinical trial investigating the 
efficacy of therapeutic hypothermia (target temperature, 33°C) versus therapeutic 
normothermia (target temperature, 36°C) in adult survivors of out-of-hospital cardiac 
arrest.8 In contrast to the earlier trials,4,5 in the recent trial involving adults, fever was 
prevented in the normothermia group through an active intervention similar to that in our 
normothermia group.8 The duration of temperature control, however, was much longer in 
our trial (120 hours vs. 36 hours). Moreover, the characteristics of our population of children 
with out-of-hospital cardiac arrest differed markedly from the population of adults with out-
of-hospital cardiac arrest, as expected. The leading cause of cardiac arrest was a respiratory 
condition in 72% of our patients, as compared with a presumed cardiac cause in all patients 
in the recent trial involving adults.8 Our trial also had a much lower proportion of patients 
with shockable rhythms (8% vs. 80%).8
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One possible explanation for the difference between the early trials of therapeutic 
hypothermia and the more recent studies is that controlled normothermia (which was used in 
the more recent trials) may be beneficial in patients with cardiac arrest. Fever commonly 
occurs after hypoxic–ischemic brain injury.3,29–31 Initial trials of therapeutic hypothermia 
for neonatal asphyxial encephalopathy and adult cardiac arrest did not prevent fever in 
control groups.4,32–34 A recent trial of cooling versus normal temperature control in neonatal 
patients at high risk for neurologic injury who were receiving ECMO support showed no 
difference in outcome or adverse effects.35 Studies of the usefulness of therapeutic 
hypothermia for traumatic brain injury in children have not shown efficacy,36 and one 
showed a trend toward higher mortality.13
Unanswered questions remain concerning the potential role of targeted temperature 
management in children after cardiac arrest. Alternative durations of therapeutic 
hypothermia temperature control (longer or shorter), different depths of temperature control 
(higher or lower), and a different therapeutic window for initiating therapeutic hypothermia 
(shorter) are modifications that might be considered for future study. Modification of 
inclusion and exclusion criteria and a combination of targeted temperature management with 
neuroprotective agents might also be considered in future trials of treatment involving 
children after cardiac arrest.37 We are currently evaluating targeted temperature 
management in children after in-hospital cardiac arrest (ClinicalTrials.gov number, 
NCT00880087); this represents a pathophysiologically distinct population, and the efficacy 
of the interventions may differ.38
In conclusion, in comatose children who survive of out-of-hospital cardiac arrest, 
therapeutic hypothermia, as compared with therapeutic normothermia, did not confer a 
significant benefit with respect to survival with good functional outcome at 1 year. Survival 
at 12 months did not differ significantly between the treatment groups.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Enrollment, Randomization, and Treatment
Scores on the Glasgow Coma Scale (GCS) motor-response subscale range from 1 to 6, with 
lower scores indicating reduced levels of function. Scores on the Pediatric Overall 
Performance Category (POPC) and Pediatric Cerebral Performance Category (PCPC) scales 
range from 1 to 6, with lower scores indicating less disability. Scores on the Vineland 
Adaptive Behavior Scales, second edition (VABS-II), range from 20 to 160, with higher 
scores indicating better function. CNS denotes central nervous system, ICU intensive care 
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unit, ITT intention to treat, and THAPCA Therapeutic Hypothermia after Pediatric Cardiac 
Arrest.
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Figure 2. Temperature of Patients during 120 Hours of Targeted Temperature Management, 
According to Treatment Group
The temperature curves show the means of all primary temperature readings within each 
time interval (for example, all primary temperature readings from 22 to 26 hours after the 
initiation of treatment are counted in the category “24 hours since initiation of treatment”). 
The I bars indicate ±2 SD from the mean temperature within each time interval. Time points 
for normothermia are slightly shifted to prevent overlap. Temperatures recorded after early 
termination of treatment are not included in this analysis.
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Table 1
Baseline Characteristics of the Patients before Randomization.*
Characteristic
Hypothermia Group
(N = 155)
Normothermia Group
(N = 140)
Demographic characteristics
Age — yr
 Median 2.1 1.6
 Interquartile range 0.6–10.1 0.4–7.0
Age category — no. (%)
 <2 yr   76 (49)   73 (52)
 2 to <12 yr   48 (31)   45 (32)
 ≥12 yr   31 (20)   22 (16)
Male sex — no. (%) 102 (66)   94 (67)
Medical history — no. (%)
No preexisting medical condition   81 (52)   71 (51)
Preexisting medical condition
 Lung or airway disease   33 (21)   34 (24)
 Neurologic condition   30 (19)   19 (14)
 Gastrointestinal disorder   19 (12)   22 (16)
 Prenatal condition   15 (10)   22 (16)
 Congenital heart disease 14 (9)   21 (15)
 Other   34 (22)   37 (26)
Characteristics of the cardiac arrest
Primary cause of the cardiac arrest — no. (%)
 Respiratory event 111 (72) 102 (73)
 Cardiovascular event 14 (9)   18 (13)
 Other 11 (7)   4 (3)
 Unknown   19 (12)   16 (11)
Bystander witnessed cardiac arrest — no./total no. (%) 58/145 (40) 51/136 (38)
Bystander performed CPR — no./total no. (%) 101/149 (68) 85/134 (63)
Initial rhythm noted by EMS or hospital — no. (%)
 Asystole   85 (55)   87 (62)
 Bradycardia   9 (6) 10 (7)
 Pulseless electrical activity   25 (16)   18 (13)
 Ventricular fibrillation or tachycardia 14 (9)   9 (6)
 Unknown   22 (14)   16 (11)
Time from cardiac arrest to CPR in 82 patients — min
 Median 3.0 2.0
 Interquartile range 0.0–7.0 0.0–8.0
Duration of CPR in 186 patients — min
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Characteristic
Hypothermia Group
(N = 155)
Normothermia Group
(N = 140)
 Median 23.0 28.0
 Interquartile range 15.0–35.0 19.0–45.0
First hospital patient arrived at was the study hospital — no. (%)   45 (29)   43 (31)
Chest compressions still required at time of arrival at first hospital — no./total no. (%) 97/152 (64) 100/137 (73)
No. of doses of epinephrine
 Administered by EMS in 270 patients†
  Median 2.0 1.0
  Interquartile range 0.0–3.0 0.0–2.0
 Administered at hospital in 289 patients†
  Median 1.0 2.0
  Interquartile range 0.0–3.0 0.0–4.0
 All doses administered by EMS and at hospital in 265 patients
  Median 3.0 3.0
  Interquartile range 2.0–4.5 2.0–5.0
*CPR denotes cardiopulmonary resuscitation, and EMS emergency medical services.
†
P<0.05 for the comparison between the two groups.
N Engl J Med. Author manuscript; available in PMC 2015 November 14.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Moler et al. Page 17
Ta
bl
e 
2
Pr
im
ar
y 
an
d 
Se
co
nd
ar
y 
O
ut
co
m
es
.*
O
ut
co
m
e
H
yp
ot
he
rm
ia
 G
ro
up
N
or
m
ot
he
rm
ia
 G
ro
up
R
isk
 D
iff
er
en
ce
R
el
at
iv
e 
Li
ke
lih
oo
d 
(95
%
 C
I)
P 
V
al
ue
n
o
./t
ot
al
 n
o.
 (%
)
pe
rc
en
ta
ge
 p
oi
nt
s (
95
% 
CI
)
Pr
im
ar
y 
ou
tc
om
e
A
liv
e 
w
ith
 V
A
BS
-II
 sc
or
e 
≥7
0 
at
 1
 y
r
27
/1
38
 (2
0)
15
/1
22
 (1
2)
7.
3 
(−
1.5
 to
 16
.1)
1.
54
 (0
.86
 to
 2.
76
)
0.
14
†
D
et
ai
le
d 
su
pp
or
tiv
e 
an
al
ys
is
0.
14
‡
D
ea
th
87
/1
38
 (6
3)
88
/1
22
 (7
2)
D
isa
bi
lit
y
 
Pr
of
ou
nd
§
16
/1
38
 (1
2)
11
/1
22
 (9
)  
 
M
od
er
at
e-
to
-s
ev
er
e¶
8/
13
8 
(6)
8/
12
2 
(7)
G
oo
d 
fu
nc
tio
na
l s
ta
tu
s‖
27
/1
38
 (2
0)
15
/1
22
 (1
2)
Se
co
nd
ar
y 
ou
tc
om
es
A
liv
e 
at
 1
 y
r
57
/1
51
 (3
8)
39
/1
36
 (2
9)
9.
1 
(−
1.8
 to
 19
.9)
1.
29
 (0
.93
 to
 1.
79
)
0.
13
†
1-
yr
 c
ha
ng
e 
in
 V
A
BS
-II
 sc
or
e 
fro
m
 b
as
el
in
e
 
 
0.
13
*
*
D
ea
th
94
/1
51
 (6
2)
97
/1
34
 (7
2)
Lo
w
es
t p
os
sib
le
 V
A
BS
-II
 sc
or
e
6/
15
1 
(4)
1/
13
4 
(1)
D
ec
re
as
e 
in
 V
A
BS
-II
 sc
or
e
 
>
30
 p
oi
nt
s
19
/1
51
 (1
3)
15
/1
34
 (1
1)
 
16
–3
0 
po
in
ts
11
/1
51
 (7
)  
4/
13
4 
(3)
 
≤1
5 
po
in
ts 
or
 im
pr
ov
ed
21
/1
51
 (1
4)
17
/1
34
 (1
3)
*
Th
e 
pr
im
ar
y 
ou
tc
om
e 
w
as
 e
va
lu
at
ed
 in
 p
at
ie
nt
s w
ith
 a
 b
as
el
in
e 
V
in
el
an
d 
A
da
pt
iv
e 
Be
ha
vi
or
 S
ca
le
s, 
se
co
nd
 e
di
tio
n 
(V
AB
S-
II)
, s
co
re 
of 
70
 or
 hi
gh
er 
at 
12
 m
on
ths
 (s
co
res
 on
 th
e V
AB
S-
II 
ran
ge
 fr
om
 20
 to
 
16
0,
 w
ith
 h
ig
he
r s
co
re
s i
nd
ic
at
in
g 
be
tte
r f
un
ct
io
n).
 T
he
 se
co
nd
ary
 ou
tco
me
s w
ere
 ev
alu
ate
d i
n a
ll p
ati
en
ts 
wi
th 
av
ail
ab
le 
da
ta.
 D
en
om
ina
tor
s r
ep
ort
ed
 ar
e f
or 
pa
tie
nts
 w
ho
se 
ou
tco
me
s w
ere
 kn
ow
n. 
CI
 
de
no
te
s c
on
fid
en
ce
 in
te
rv
al
.
† T
he
 P
 v
al
ue
 w
as
 c
al
cu
la
te
d 
by
 m
ea
ns
 o
f t
he
 C
oc
hr
an
–M
an
te
l–
H
ae
ns
ze
l t
es
t, 
w
ith
 a
dju
stm
en
t fo
r a
ge
 ca
teg
ory
.
‡ T
he
 P
 v
al
ue
 w
as
 c
al
cu
la
te
d 
by
 m
ea
ns
 o
f t
he
 M
an
n–
W
hi
tn
ey
 te
st 
on
 th
e 
ba
sis
 o
f t
he
 1
-y
ea
r c
on
tin
uo
us
 V
A
BS
-II
 sc
or
e,
 st
ra
tif
ie
d 
ac
co
rd
in
g 
to
 a
ge
 c
at
eg
or
y.
 D
ec
ea
se
d 
pa
tie
nt
s a
nd
 th
os
e 
w
ith
 th
e 
lo
w
es
t 
po
ss
ib
le
 V
A
BS
-II
 sc
or
e 
w
er
e 
as
sig
ne
d 
ra
nk
s o
f −
20
00
 a
nd
 −
10
00
, r
es
pe
ct
iv
el
y 
(i.
e.,
 th
e w
ors
t p
os
sib
le 
sco
res
).
§ P
ro
fo
un
d 
di
sa
bi
lit
y 
w
as
 d
ef
in
ed
 a
s a
 V
A
BS
-II
 sc
or
e 
of
 le
ss
 th
an
 4
5 
or
 th
e l
ow
es
t p
os
sib
le
 sc
or
e.
N Engl J Med. Author manuscript; available in PMC 2015 November 14.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Moler et al. Page 18
¶ M
od
er
at
e-
to
-s
ev
er
e 
di
sa
bi
lit
y 
w
as
 d
ef
in
ed
 a
s a
 V
A
BS
-II
 sc
or
e 
of
 4
5 
to
 6
9.
‖ G
oo
d 
fu
nc
tio
na
l s
ta
tu
s w
as
 d
ef
in
ed
 a
s a
 V
A
BS
-II
 sc
or
e 
of
 7
0 
or
 h
ig
he
r.
*
*
Th
e 
P 
va
lu
e 
w
as
 c
al
cu
la
te
d 
by
 m
ea
ns
 o
f t
he
 M
an
n–
W
hi
tn
ey
 te
st 
on
 th
e 
ba
sis
 o
f t
he
 c
on
tin
uo
us
 c
ha
ng
e 
in
 V
A
BS
-II
 sc
or
e,
 st
ra
tif
ie
d 
ac
co
rd
in
g 
to
 a
ge
 c
at
eg
or
y.
 D
ec
ea
se
d 
pa
tie
nt
s a
nd
 th
os
e 
w
ith
 th
e 
lo
w
es
t 
po
ss
ib
le
 V
A
BS
-II
 sc
or
e 
w
er
e 
as
sig
ne
d 
ra
nk
s o
f −
20
00
 a
nd
 −
10
00
, r
es
pe
ct
iv
el
y 
(i.
e.,
 th
e w
ors
t p
os
sib
le 
sco
res
).
N Engl J Med. Author manuscript; available in PMC 2015 November 14.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Moler et al. Page 19
Table 3
Safety Outcomes within 7 Days after Randomization and 28-Day Mortality.
Outcome
Hypothermia Group
(N = 153)
Normothermia Group
(N = 139) P Value*
Blood-product use — no./total no. (%)
 Any 83/153 (54) 74/138 (54) 0.92
 Type
  Cryoprecipitate 13/153 (8)  12/137 (9)  0.94
  Fresh-frozen plasma 50/153 (33) 41/138 (30) 0.59
  Packed red cells or whole blood 65/153 (42) 59/137 (43) 0.92
  Platelets 19/153 (12) 12/137 (9)  0.32
Arrhythmias — no./total no. (%)
 Serious 17/153 (11) 13/137 (9)  0.66
 Type
  Asystole 6/153 (4) 5/137 (4) 0.91
  Atrial (supraventricular tachycardia, atrial flutter, junctional ectopic 
tachycardia)
4/153 (3) 2/137 (1) 0.53
  Pulseless electrical activity 1/153 (1) 0/137     0.53
  Ventricular (sustained ventricular tachycardia >30 sec, ventricular 
fibrillation, torsades)
5/153 (3) 5/137 (4) 0.86
  Other 7/153 (5) 2/137 (1) 0.14
Culture-proven infections
 Any — no./total no. (%) 70/153 (46) 54/137 (39) 0.28
 No. of infections 109 76
 No. of days at risk 978 765
 Rate of infections/100 days (95% CI)† 11.1 (9.2–13.4) 9.9 (7.8–12.4)  0.46†
All-cause mortality 28 days — no./total no. (%) 87/153 (57) 93/139 (67) 0.08
*
P values for all comparisons, except where noted, are two-sided mid-P values, based on an exact likelihood-ratio test.
†Confidence intervals are exact two-sided 95% confidence intervals, and the P value is based on an exact test of homogeneity of event rates 
between the hypothermia group and the normothermia group, assuming that event data follow Poisson distributions.
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